ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements with these filters
Welcure Drugs & Pharmaceuticals approved the closure of its Ahmedabad corporate office. Operations will continue uninterrupted with records transferred to the registered office.
Welcure Drugs submitted its Annual Secretarial Compliance Report for FY2026 under Regulation 24A. The report confirms overall compliance while noting historical fines paid for earlier procedural delays.
Welcure Drugs & Pharmaceuticals Ltd reported a net loss of ₹49.9 Cr for Q4 FY26.
Welcure Drugs and Pharmaceuticals reported annual total income of ₹367.00 Crore for FY26. The Board approved audited results, showing a net annual loss of ₹5.49 Crore.
Welcure Drugs scheduled a board meeting for May 29, 2026. Directors will consider and approve audited financial results for the 2026 fiscal year.
Welcure Drugs & Pharmaceuticals Ltd confirmed it does not meet SEBI's 'Large Corporate' criteria for the financial year ended March 31, 2026. Consequently, the company is exempt from mandatory incremental borrowing through debt securities. Its outstanding borrowings as of the reporting date were nil.